First Day of Dealings

Angle PLC
17 March 2004

For Immediate Release:                                            17 March 2004


                                   ANGLE plc

       First Day of Dealings on the Alternative Investment Market ('AIM')


ANGLE plc ('ANGLE' or the 'Group', AIM: AGL), the venture management and
consulting company specialising in the commercialisation of technology, is
pleased to announce its flotation on the Alternative Investment Market of the
London Stock Exchange ('AIM') today.

  • ANGLE Technology was established in April 1994 by former executives
    from KPMG's High Technology Consulting Group.

  • ANGLE has built a management team experienced in the commercialisation of
    technology. The Directors believe that ANGLE will play a role in bridging
    the gap between research and technology and business and finance.

  • £9 million (before expenses) was raised for ANGLE via a Placing of
    6.25 million Ordinary Shares at the Placing price of 144p per Ordinary Share
    (the 'Placing Price') by KBC Peel Hunt Ltd.

  • On Admission, the market capitalisation at the Placing Price will be
    £24.0 million.

  • ANGLE will use the net proceeds of the Placing for working capital
    principally to enable it to further finance and develop its business
    strategy, including:

    -  building the Ventures business leading to the establishment and
       development of new Progeny(R) Companies;

    -  accelerating the growth of the Consulting and Management businesses
       through the provision of resources for expansion of the professional 
       team;


Andrew Newland, Chief Executive of ANGLE plc, commented:

'I am delighted with the response to ANGLE's flotation.

With the funds raised from the Placing and a heightened profile on AIM, we look
forward to pursuing our objectives of expanding our Consulting and Management
businesses as well as founding and growing more IP backed technology companies.'



                            INFORMATION ON THE GROUP


Consulting and Management businesses

ANGLE has built Consulting and Management businesses in the UK and US, which
provide revenues as well as relationships with corporates, government research
establishments and universities. In December 2003, ANGLE secured a substantial
management contract in the Middle East.


Management combining technological understanding and business experience

The Directors believe that the successful development of new technology
companies requires technology, finance and management and that management
deficiency is one of the barriers to

successfully realising the commercial potential of new technological
innovations. ANGLE employees combine a technological understanding with business
experience allowing ANGLE to play a role in bridging the gap between research
and technology and business and finance.


Working relationships with research establishments providing preferential access
to new technology

Through its Consulting and Management businesses, ANGLE has established working
relationships with a number of research establishments which have proprietary
technology for commercialisation. Working relationships have now been
established with over eighty clients developing proprietary technology including
over thirty five corporates (such as BT), over ten public sector research
organisations (such as Dstl) and over thirty universities (such as the
Universities of Virginia and Pennsylvania, US).


Progeny(R), a systematic process for establishing new technology companies

ANGLE has developed Progeny(R), a systematic process for establishing new
technology companies. The application of Progeny(R) to the UK biotechnology
sector has been recognised and financially supported by the DTI. ANGLE achieved
this recognition after they were one of only two winners in 1998 of the
prestigious BMI Challenge competition organised by the UK Government.


Substantial equity positions in five technology companies

ANGLE has established and retains substantial equity positions in five
technology companies:
Acolyte Biomedica Limited, Exago Limited, IDR Therapeutics LLC, NeuroTargets
Limited and Provexis Limited.


Other technology opportunities

The Directors believe that the potential exists for establishing more Progeny(R)
Companies in the future in such areas as IT, electronics, biotechnology and
other technology sub-sectors.


Scaleable diversified business building a portfolio of technology companies

ANGLE's business is scaleable, diversified into international markets, and is
based on revenue generating Consulting and Management businesses and a portfolio
of companies in a number of technology sectors ranging from IT to biotechnology.



PLACING STATISTICS

Placing Price                                                                  144 pence
Number of new Ordinary Shares being issued under the Placing                   6,250,000
Market capitalisation following the Placing at the Placing Price             £24,042,937
Number of Ordinary Shares in issue on Admission                               16,696,484
Percentage of enlarged issued share capital being subject to the Placing          37.43%
Gross proceeds of the Placing                                               £9.0 million
Net proceeds to be received by the Company (exclusive of applicable VAT)    £8.2 million



For further information, please contact:

ANGLE plc                                                        01483 295830
Andrew Newland, Chief Executive
Dawson Buck, Deputy Chief Executive
Ian Griffiths, Finance Director

Buchanan Communications                                          020 7466 5000
Richard Darby
Suzanne Brocks

KBC Peel Hunt                                                    020 7418 8900
Adam Hart
David Anderson



                      This information is provided by RNS
            The company news service from the London Stock Exchange